11:02 AM EDT, 09/16/2024 (MT Newswires) -- UroGen Pharma ( URGN ) said Monday that it has received a notice of allowance from the US Patent and Trademark Office for a patent related to its cancer treatment methods.

The patent provides intellectual property coverage of the company's RTGel technology combined with medac's licensed proprietary lyophilized mitomycin formulation, covering the use of UroGen's UGN-103 and UGN-104 development programs for treating certain types of bladder and upper tract cancers.

The patent will last until December 2041 once issued, the company added.

Shares of UroGen rose 4.1% in recent trading.

Price: 13.66, Change: +0.54, Percent Change: +4.08